Trial · NCT03710291
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression of chronic kidney disease | Through study completion, up to approximately 6 years. | Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death. |
| Secondary | Death (all-cause), ESRD or a confirmed ≥50% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of: death (all-cause); ESRD; a confirmed ≥50% reduction in eGFR. |
| Secondary | Physical functioning (subjective) | 18 months after randomization. | Kidney Disease Quality of Life Physical Functioning Survey. |
| Secondary | Physical functioning (objective) | 18 months after randomization. | Repeated chair stand test. |
| Secondary | ESRD or renal death | Through study completion, up to approximately 6 years. | Time to ESRD or renal death. |
| Secondary | Primary outcome measure OR cardiovascular death | Through study completion, up to approximately 6 years. | Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death; cardiovascular death. |
| Secondary | Serum creatinine | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed doubling of serum creatinine. |
| Secondary | ≥50% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed ≥50% reduction in eGFR. |
| Secondary | ≥40% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed ≥40% reduction in eGFR. |
| Secondary | All-cause hospitalization | Through study completion, up to approximately 6 years. | Frequency of all-cause hospitalization. |
| Secondary | Cardiovascular death | Through study completion, up to approximately 6 years. | Time to cardiovascular death. |
| Secondary | All-cause mortality | Through study completion, up to approximately 6 years. | Time to all-cause mortality. |
| Other | Safety of TRC101 | Through study completion, up to approximately 6 years. | Frequency, intensity, and relationship to study drug of adverse events and serious adverse events. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03710291/registered